How much did AbbVie achieve in EBIT for the current year?
In the current year, AbbVie has achieved an EBIT of 25.32 B USD.
AbbVie EBIT 2024
AbbVie EBIT
25.32 B USD
Ticker
ABBV
ISIN
US00287Y1091
WKN
A1J84E
In 2024, AbbVie's EBIT was 25.32 B USD, a 52.98% increase from the 16.55 B USD EBIT recorded in the previous year.
The AbbVie EBIT history
| YEAR | EBIT (undefined USD) |
|---|---|
| 2029e | - |
| 2028e | 36.61 |
| 2027e | 33.83 |
| 2026e | 30.74 |
| 2025e | 28.29 |
| 2024e | 25.32 |
| 2023 | 16.55 |
| 2022 | 20.12 |
| 2021 | 19.47 |
| 2020 | 13.07 |
| 2019 | 13.32 |
| 2018 | 12.07 |
| 2017 | 9.8 |
| 2016 | 9.6 |
| 2015 | 7.87 |
| 2014 | 3.76 |
| 2013 | 6.02 |
| 2012 | 6.3 |
| 2011 | 4.5 |
| 2010 | 5.18 |
| 2009 | 5.13 |
AbbVie Revenue, EBIT, Net Income US00287Y1091 · A1J84E
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into AbbVie, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by AbbVie from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects AbbVie’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of AbbVie. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into AbbVie’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing AbbVie’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on AbbVie’s growth potential.
AbbVie Revenue, EBIT and net profit per share
| Date | AbbVie Revenue | AbbVie EBIT | AbbVie Net Income |
|---|---|---|---|
| 2029e | 74.63 B undefined | 0 undefined | 31.27 B undefined |
| 2028e | 71.83 B undefined | 36.61 B undefined | 28.81 B undefined |
| 2027e | 67.6 B undefined | 33.83 B undefined | 26.39 B undefined |
| 2026e | 64.2 B undefined | 30.74 B undefined | 24.38 B undefined |
| 2025e | 59.85 B undefined | 28.29 B undefined | 21.78 B undefined |
| 2024e | 56.8 B undefined | 25.32 B undefined | 19.61 B undefined |
| 2023 | 54.32 B undefined | 16.55 B undefined | 4.82 B undefined |
| 2022 | 58.05 B undefined | 20.12 B undefined | 11.78 B undefined |
| 2021 | 56.2 B undefined | 19.47 B undefined | 11.47 B undefined |
| 2020 | 45.8 B undefined | 13.07 B undefined | 4.56 B undefined |
| 2019 | 33.27 B undefined | 13.32 B undefined | 7.84 B undefined |
| 2018 | 32.75 B undefined | 12.07 B undefined | 5.66 B undefined |
| 2017 | 28.22 B undefined | 9.8 B undefined | 5.28 B undefined |
| 2016 | 25.64 B undefined | 9.6 B undefined | 5.92 B undefined |
| 2015 | 22.86 B undefined | 7.87 B undefined | 5.14 B undefined |
| 2014 | 19.96 B undefined | 3.76 B undefined | 1.77 B undefined |
| 2013 | 18.79 B undefined | 6.02 B undefined | 4.13 B undefined |
| 2012 | 18.38 B undefined | 6.3 B undefined | 5.28 B undefined |
| 2011 | 17.44 B undefined | 4.5 B undefined | 3.43 B undefined |
| 2010 | 15.64 B undefined | 5.18 B undefined | 4.18 B undefined |
| 2009 | 14.21 B undefined | 5.13 B undefined | 4.64 B undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2009 | 14.21 B USD | 5.13 B USD | 4.64 B USD |
| 2010 | 15.64 B USD | 5.18 B USD | 4.18 B USD |
| 2011 | 17.44 B USD | 4.5 B USD | 3.43 B USD |
| 2012 | 18.38 B USD | 6.3 B USD | 5.28 B USD |
| 2013 | 18.79 B USD | 6.02 B USD | 4.13 B USD |
| 2014 | 19.96 B USD | 3.76 B USD | 1.77 B USD |
| 2015 | 22.86 B USD | 7.87 B USD | 5.14 B USD |
| 2016 | 25.64 B USD | 9.6 B USD | 5.92 B USD |
| 2017 | 28.22 B USD | 9.8 B USD | 5.28 B USD |
| 2018 | 32.75 B USD | 12.07 B USD | 5.66 B USD |
| 2019 | 33.27 B USD | 13.32 B USD | 7.84 B USD |
| 2020 | 45.8 B USD | 13.07 B USD | 4.56 B USD |
| 2021 | 56.2 B USD | 19.47 B USD | 11.47 B USD |
| 2022 | 58.05 B USD | 20.12 B USD | 11.78 B USD |
| 2023 | 54.32 B USD | 16.55 B USD | 4.82 B USD |
| 2024e | 56.8 B USD | 25.32 B USD | 19.61 B USD |
| 2025e | 59.85 B USD | 28.29 B USD | 21.78 B USD |
| 2026e | 64.2 B USD | 30.74 B USD | 24.38 B USD |
| 2027e | 67.6 B USD | 33.83 B USD | 26.39 B USD |
| 2028e | 71.83 B USD | 36.61 B USD | 28.81 B USD |
| 2029e | 74.63 B USD | 0 USD | 31.27 B USD |
AbbVie stock margins US00287Y1091 · A1J84E
The AbbVie margin analysis displays the gross margin, EBIT margin, as well as the profit margin of AbbVie. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for AbbVie.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the AbbVie's sales revenue. A higher gross margin percentage indicates that the AbbVie retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the AbbVie's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the AbbVie's total revenue generated. When comparing the revenue margin year over year, investors can gauge the AbbVie's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the AbbVie. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the AbbVie's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
AbbVie Margin History
| AbbVie Gross margin | AbbVie Profit margin | AbbVie EBIT margin | AbbVie Profit margin |
|---|---|---|---|
| 2029e | 66.45 % | 0 % | 41.89 % |
| 2028e | 66.45 % | 50.98 % | 40.11 % |
| 2027e | 66.45 % | 50.05 % | 39.05 % |
| 2026e | 66.45 % | 47.88 % | 37.97 % |
| 2025e | 66.45 % | 47.27 % | 36.39 % |
| 2024e | 66.45 % | 44.58 % | 34.53 % |
| 2023 | 66.45 % | 30.47 % | 8.87 % |
| 2022 | 71.53 % | 34.66 % | 20.29 % |
| 2021 | 69.19 % | 34.65 % | 20.41 % |
| 2020 | 66.69 % | 28.53 % | 9.95 % |
| 2019 | 77.14 % | 40.04 % | 23.57 % |
| 2018 | 76.93 % | 36.85 % | 17.27 % |
| 2017 | 74.63 % | 34.74 % | 18.72 % |
| 2016 | 77.32 % | 37.46 % | 23.1 % |
| 2015 | 80.31 % | 34.43 % | 22.5 % |
| 2014 | 77.83 % | 18.85 % | 8.89 % |
| 2013 | 75.62 % | 32.02 % | 21.97 % |
| 2012 | 75.47 % | 34.28 % | 28.7 % |
| 2011 | 73.64 % | 25.79 % | 19.68 % |
| 2010 | 72.59 % | 33.11 % | 26.72 % |
| 2009 | 71.46 % | 36.08 % | 32.62 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2009 | 71.46 % | 36.08 % | 32.62 % |
| 2010 | 72.59 % | 33.11 % | 26.72 % |
| 2011 | 73.64 % | 25.79 % | 19.68 % |
| 2012 | 75.47 % | 34.28 % | 28.7 % |
| 2013 | 75.62 % | 32.02 % | 21.97 % |
| 2014 | 77.83 % | 18.85 % | 8.89 % |
| 2015 | 80.31 % | 34.43 % | 22.5 % |
| 2016 | 77.32 % | 37.46 % | 23.1 % |
| 2017 | 74.63 % | 34.74 % | 18.72 % |
| 2018 | 76.93 % | 36.85 % | 17.27 % |
| 2019 | 77.14 % | 40.04 % | 23.57 % |
| 2020 | 66.69 % | 28.53 % | 9.95 % |
| 2021 | 69.19 % | 34.65 % | 20.41 % |
| 2022 | 71.53 % | 34.66 % | 20.29 % |
| 2023 | 66.45 % | 30.47 % | 8.87 % |
| 2024e | 66.45 % | 44.58 % | 34.53 % |
| 2025e | 66.45 % | 47.27 % | 36.39 % |
| 2026e | 66.45 % | 47.88 % | 37.97 % |
| 2027e | 66.45 % | 50.05 % | 39.05 % |
| 2028e | 66.45 % | 50.98 % | 40.11 % |
| 2029e | 66.45 % | 0 % | 41.89 % |
AbbVie Aktienanalyse
What does AbbVie do?
Abbvie Inc. is a global, research-oriented company specializing in the field of biotechnology and pharmaceuticals. It was founded in 2013 as a spin-off from Abbott Laboratories. Abbvie's headquarters are in North Chicago, Illinois, and it employs over 47,000 people in more than 75 countries worldwide. The company focuses on researching, developing, and marketing high-quality therapies for the treatment of serious and life-threatening diseases. Abbvie has several business divisions, including immunology, oncology, neurology, and virology, and is known for its investments in research and development. Its key products include adalimumab (sold under the brand name Humira) for autoimmune diseases and Imbruvica for chronic lymphocytic leukemia. Abbvie is recognized as a leading company in the biotechnology and pharmaceutical industry due to its focus on innovative therapies and medicines. AbbVie ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing AbbVie's EBIT
AbbVie's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of AbbVie's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
AbbVie's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in AbbVie’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about AbbVie stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company AbbVie.
How has the EBIT of AbbVie developed in recent years?
The EBIT of AbbVie has increased by 52.975% increased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company AbbVie?
The EBIT of AbbVie is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does AbbVie pay?
Over the past 12 months, AbbVie paid a dividend of 5.92 USD . This corresponds to a dividend yield of about 3.06 %. For the coming 12 months, AbbVie is expected to pay a dividend of 6.04 USD.
What is the dividend yield of AbbVie?
The current dividend yield of AbbVie is 3.06 %.
When does AbbVie pay dividends?
AbbVie pays a quarterly dividend. This is distributed in the months of February, May, August, November.
How secure is the dividend of AbbVie?
AbbVie paid dividends every year for the past 101 years.
What is the dividend of AbbVie?
For the upcoming 12 months, dividends amounting to 6.04 USD are expected. This corresponds to a dividend yield of 3.12 %.
In which sector is AbbVie located?
AbbVie is assigned to the 'Health' sector.
Wann musste ich die Aktien von AbbVie kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of AbbVie from 11/15/2024 amounting to 1.55 USD, you needed to have the stock in your portfolio before the ex-date on 10/15/2024.
When did AbbVie pay the last dividend?
The last dividend was paid out on 11/15/2024.
What was the dividend of AbbVie in the year 2023?
In the year 2023, AbbVie distributed 5.64 USD as dividends.
In which currency does AbbVie pay out the dividend?
The dividends of AbbVie are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The AbbVie stock can be added to a savings plan with the following providers: Trade Republic, Scalable Capital and Consorsbank
Andere Kennzahlen von AbbVie
Our stock analysis for AbbVie Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AbbVie Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
